Australia markets closed

AVXL Jan 2024 3.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
9.500.00 (0.00%)
As of 08:53AM EST. Market open.
Full screen
Previous close9.50
Open9.50
Bid8.00
Ask13.00
Strike3.00
Expiry date2024-01-19
Day's range9.50 - 9.50
Contract rangeN/A
Volume1
Open interest17
  • Motley Fool

    Why Shares of Anavex Life Sciences Slumped 23.5% on Monday

    What happened Shares of Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday.

  • GlobeNewswire

    Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

    Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ETNEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financ